Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 30Burkitt Lymphoma 12Lung Neoplasms 11Leukemia, Myeloid, Acute 11Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 4Lymphoma, B-Cell 4Leukemia 4Wilms Tumor 3Sarcoma, Ewing 3Plasmablastic Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Immunoblastic Lymphadenopathy 3Ganglioneuroblastoma 3Teratoma 2Sarcoma 2

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Etoposide × 90 days × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡